Cargando…

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review

PURPOSE: Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Windisch, Paul, Zwahlen, Daniel R., Giesel, Frederik L., Scholz, Eberhard, Lugenbiel, Patrick, Debus, Jürgen, Haberkorn, Uwe, Adeberg, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895887/ https://www.ncbi.nlm.nih.gov/pubmed/33606104 http://dx.doi.org/10.1186/s13550-021-00761-2

Ejemplares similares

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review
por: Windisch, Paul, et al.
Publicado: (2020)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
por: Dendl, Katharina, et al.
Publicado: (2021)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT
por: Koerber, Stefan A., et al.
Publicado: (2021)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
por: Syed, M., et al.
Publicado: (2020)

FAP-Specific Signalling Is an Independent Diagnostic Approach in ACC and Not a Surrogate Marker of MRI Sequences
por: Liew, Dawn P., et al.
Publicado: (2022)

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
por: Dendl, K., et al.
Publicado: (2021)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

(68)Ga-FAPI-PET/CT in patients with various gynecological malignancies
por: Dendl, Katharina, et al.
Publicado: (2021)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging
por: Kessel, Katharina, et al.
Publicado: (2021)

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
por: Loktev, Anastasia, et al.
Publicado: (2018)

Targeting of activated fibroblasts for imaging and therapy
por: Lindner, Thomas, et al.
Publicado: (2019)

(18)F-labeled tracers targeting fibroblast activation protein
por: Lindner, Thomas, et al.
Publicado: (2021)

Dataset of voxelwise correlated signal values of ADC, rCBV and FAP-specific PET of 13 Glioblastoma patients
por: Röhrich, Manuel, et al.
Publicado: (2020)

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas
por: Dittmar, Jan Oliver, et al.
Publicado: (2017)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review
por: Arçay Öztürk, Ayça, et al.
Publicado: (2023)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

Impact of (18)F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy
por: Debus, Charlotte, et al.
Publicado: (2018)

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

Dose-Limiting Organs at Risk in Carbon Ion Re-Irradiation of Head and Neck Malignancies: An Individual Risk-Benefit Tradeoff
por: Held, Thomas, et al.
Publicado: (2019)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

APC(+/−) alters colonic fibroblast proteome in FAP
por: Patel, Bhavinkumar B., et al.
Publicado: (2011)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer
por: Liermann, Jakob, et al.
Publicado: (2021)

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer
por: Ristau, J., et al.
Publicado: (2020)

Feasibility and robustness of dynamic (18)F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation
por: Debus, Charlotte, et al.
Publicado: (2018)

Design, Synthesis and Preclinical Assessment of (99m)Tc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging
por: Trujillo-Benítez, Diana, et al.
Publicado: (2022)

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA
por: Backhaus, P., et al.
Publicado: (2021)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

Fibroblast activation protein (FAP) as a novel metabolic target
por: Sánchez-Garrido, Miguel Angel, et al.
Publicado: (2016)

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
por: Zboralski, Dirk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_inad7451l4efg8ivr4n4e4mcn7